Výsledky vyhledávání - "Yong-Gyu Son"

Akademický článek

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

Autor: Eunhee Lee, Yong-Gyu Son, Shinai Lee, Yangmi Lim, Jonghwa Won, Sumyeong Park, Jiseon Yoo, Youngil Koh, Dong-Yeop Shin

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)

Background Acute myeloid leukemia (AML) is a type of leukemia in adults with a high mortality rate and poor prognosis. Although targeted therapeutics, chemotherapy, and hematopoietic stem cell transplantation can improve the prognosis, the recurrence

Externí odkaz: https://doaj.org/article/cc1ad51e12d040fa80953ba783a4336c

Zobrazit plný text záznamu

Akademický článek

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)

Background Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs. However, dose-dependent hepatotoxicity was observed

Externí odkaz: https://doaj.org/article/f928715e9bd14a19be6842809c144bf9

Zobrazit plný text záznamu

Akademický článek

N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

Autor: Min Ji Ko, Daehae Song, Juhee Kim, Jae Yong Kim, Jaehyun Eom, Byungje Sung, Yong-Gyu Son, Young Min Kim, Sang Hoon Lee, Weon-Kyoo You, Jinwon Jung

Publikováno v: mAbs, Vol 13, Iss 1 (2021)

Antibody–drug conjugates (ADCs) are targeted therapeutic agents that treat cancers by selective delivery of highly potent cytotoxic drugs to tumor cells via cancer-specific antibodies. However, their clinical benefit is limited by off-target toxici

Externí odkaz: https://doaj.org/article/2dbd7df1c4d047828bca0a29a4ffbb29

Zobrazit plný text záznamu

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

Publikováno v: Molecular Therapy. 30:2800-2816

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with other checkpoint inhibitors. Lymphocyte-activation gene 3 (LAG-3) is an i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a56d0128b6f787ced7cc412d81543db9
https://doi.org/10.1016/j.ymthe.2022.05.003

Zobrazit plný text záznamu

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 + tumor-infiltrating lymphocytes

Publikováno v: Science Advances. 7

Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb09c064bc95e7a137574a83469293c3
https://doi.org/10.1126/sciadv.aax3160

Zobrazit plný text záznamu

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8

Publikováno v: Science Advances

Tumor-targeted T cell costimulatory antibody augments antitumor immunity by enhancing tumor-killing T cells within the tumor.
Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. He

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2aabd32c75c85658a5b999d46b4b430c
https://pubmed.ncbi.nlm.nih.gov/33523913

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání